{
    "ticker": "KTTA",
    "name": "Kintara Therapeutics, Inc.",
    "description": "Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer. Founded in 2016 and headquartered in San Diego, California, Kintara is dedicated to improving the lives of patients through the advancement of its proprietary drug candidates. The company's lead product, VAL-083, is being developed for the treatment of various cancers, including glioblastoma multiforme, a highly aggressive brain cancer. Kintara's approach combines established therapeutic modalities with novel mechanisms of action to target cancer cells effectively. The company is also advancing a pipeline of other drug candidates that aim to address unmet medical needs in oncology. Kintara's commitment to scientific rigor and collaboration with leading academic institutions and clinical centers underpins its strategy to bring transformative therapies to market. As Kintara continues to progress its clinical trials and expand its research capabilities, it strives to make a significant impact in the fight against cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2016",
    "website": "https://www.kintaratx.com",
    "ceo": "Saiid Zarrabian",
    "social_media": {
        "twitter": "https://twitter.com/KintaraTx",
        "linkedin": "https://www.linkedin.com/company/kintara-therapeutics/"
    },
    "investor_relations": "https://www.kintaratx.com/investors",
    "key_executives": [
        {
            "name": "Saiid Zarrabian",
            "position": "CEO"
        },
        {
            "name": "Jeffrey W. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drug Candidates",
            "products": [
                "VAL-083",
                "Kintara's Pipeline Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kintara Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Kintara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Learn about their lead product VAL-083 and ongoing research.",
        "keywords": [
            "Kintara Therapeutics",
            "Cancer Treatment",
            "VAL-083",
            "Biopharmaceuticals",
            "Oncology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Kintara Therapeutics known for?",
            "answer": "Kintara Therapeutics is known for developing innovative therapies for the treatment of cancer, particularly its lead product VAL-083."
        },
        {
            "question": "Who is the CEO of Kintara Therapeutics?",
            "answer": "Saiid Zarrabian is the CEO of Kintara Therapeutics, Inc."
        },
        {
            "question": "Where is Kintara Therapeutics headquartered?",
            "answer": "Kintara Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Kintara's main products?",
            "answer": "Kintara's main product is VAL-083, along with a pipeline of other oncology drug candidates."
        },
        {
            "question": "When was Kintara Therapeutics founded?",
            "answer": "Kintara Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "CLVS",
        "ADAP",
        "NTRA",
        "PBYI"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}